Getting new drugs into the hands of patients can take decades and cost billions of euros. With the aging European population, rise of chronic diseases, and the constant development of innovative (and expensive) treatments for illnesses such as cancer, the demand for new medicines and treatments will only continue to grow through the end of the decade.
Real world evidence is increasingly lauded as the solution to accelerating market access processes, achieving better reimbursement rates, and showing how medicines can perform outside tightly controlled clinical trial settings. The European life sciences industry’s use of real world evidence is underdeveloped compared to its North American counterparts, and the full-scale adoption of real world data and evidence have the power to completely reshape the existing life science industry.
19th-20th January 2017, Frankfurt, Germany
The event will be taking place from January 19-20 at the Leonardo Royal Hotel Frankfurt, a 4-star skyscraper hotel in Frankfurt’s Sachsenhausen district. The hotel is just a 5-minute ride from downtown and Frankfurt Central Station. It is located at Mailänder Straße 1, 60598 Frankfurt / Main, Germany and online at web page
VP, (Senior) Director, Head, (Senior) Manager of:
• Real World Data/Evidence
• Market Access
• Medical Affairs
• Health Economics
• Outcomes Research
• Pricing and/or Reimbursement
• Medical Devices
• Life Sciences
Do you think your experience and knowledge can contribute to the agenda?
Are you interested in presenting a case study on behalf of your company?